Abstract Background Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a
crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving …

The availability of immune-checkpoint inhibitors (ICI) in the last decade has resulted in a
paradigm shift in certain areas of oncology. Patients can be treated either by a monotherapy …

Immune-checkpoint inhibitors show promising effects in the treatment of multiple tumor
types. Biomarkers are biological indicators used to select patients for a systemic anticancer …

The combination of targeted therapy with immune checkpoint inhibition (ICI) is an area of
intense interest. We studied the interaction of fibroblast growth factor receptor (FGFR) …

Abstract Introduction Cancer‐associated fibroblasts (CAFs) are correlated with the
immunotherapy response. However, the culprits that link CAFs to immunotherapy resistance …

Fibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal
development and contributes to tissue and whole-body homeostasis, but can also promote …

Purpose: Erdafitinib is the only FDA-approved targeted therapy for FGFR2/3-altered
metastatic urothelial cancer. We characterized the genetic landscape of FGFR-altered …

Abstract Background N6-methyladenosine (m6A) RNA methylation plays a critical role in key
genetic events for various cancers; yet, how m6A functions within the tumor …

Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains incurable,
with 5-year survival rates of approximately 10%. Platinum-based chemotherapy has a major …

Pyroptosis has profound impacts on tumor cell proliferation, invasion, and metastasis and is
of great clinical significance for different cancers. However, the role of pyroptosis in the …